JNJ Related Earnings News
-
Jefferies Trims Estimates, Ups PT on Johnson & Johnson (JNJ) Post Q1
-
Goldman Maintains Sell on Johnson & Johnson (JNJ); Drug Business Spin Still Unlikely
-
Johnson & Johnson (JNJ) Sees FY13 Revs at $70.4B - $71.1B; Est. at $71.1B
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 3c; Reaffirms FY EPS Outlook
-
Q1 Not Super Important for Johnson & Johnson (JNJ), But New Products Are - UBS
-
Johnson & Johnson (JNJ) Sees 4c/Share Hit on EPS From Bolivar Devaluation
-
Johnson & Johnson (JNJ) Reports Q4 Results, Ticks Lower as FY Guidance Falls Short
-
J&J (JNJ) Guides FY13 Reported Revs Below Consensus
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; Guides FY13 EPS Below Views
-
Johnson & Johnson (JNJ) Provides Investors Positive Q3 Surprise
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 4c; Boosts FY12 EPS Outlook
-
Refinancing of Debt Helps Alkermes (ALKS) Save Cash, MKM Reiterates Buy, Raises PT
-
Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT on Early Approval
-
Maxim Upgrades Dendreon (DNDN) as the Street is 'Too Bearish' Ahead of Q2 Results
-
RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results
-
J&J (JNJ) Reports 3% Rise in Q2 Profit; Reduced FY12 Guidance Weighs
-
J&J (JNJ) Reports In-Line Q2 EPS of $1.30; Cuts FY12 Outlook
-
Q2 Preview: Eyes on J&J's (JNJ) New CEO Gorsky Into Print, Conference Call
-
Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT and 2013 Estimates
-
Auriga Maintains a 'Buy' on Perrigo Co. (PRGO); Accumulate Shares on Weakness
-
UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Held Back By Slow EPS Growth
-
Johnson & Johnson (JNJ) volatility low into Q1 sales of $16.1B
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 2c; Raises FY12 EPS Guidance
-
Q1 Preview: Bellwether Johnson & Johnson (JNJ) has New CEO, Patent Expiration on Its Plate
-
Merck (MRK) Shows Strong Earnings Following M&A Adjustments; Outlook Flat
-
Q4 Preview: Pfizer (PFE) May Suffer Same Ailment as Peers: Strong Dollar Syndrome
-
Highlights From JNJ's Q4 Conference Call: International and Consumer Brands Up, Procedures Down
-
Johnson & Johnson (JNJ) Beats Q4 Views, But Offers Muted Guidance
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 3c; Guides FY12 Below the Street
-
Symmetry Medical (SMA) Completes Acquisition of Codman & Shurtleff, Inc., Offers New FY12 Guidance
-
Q3 Preview: Analysts Cautious on 3M (MMM) into Results on Peer Warnings
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 3c; Boosts FY11 Outlook
-
Q3 Preview: Johnson & Johnson (JNJ) Kicks Off Pharma Earnings; May Face Headwinds from FX, Generics
-
Highlights From JNJ's Q2 Conference Call: Worldwide Sales Increased 8.3%; Net Earnings Up 4.9%
-
JNJ (JNJ) Makes Investors Think Following Q2 Beat as FY11 Outlook Maintained
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 5c; Reaffirms Guidance
-
Highlights From JNJ's Q1 Conference Call: U.S. Sales Declined by 0.6%; Total Worldwide Revenues Increased 3.5%
-
J&J (JNJ) Offers FY11 Sales Guidance on Conference Call
-
Johnson & Johnson (JNJ) Issues Q1 'Beat-and-Raise' Led By Pharma Business
-
Johnson & Johnson (JNJ) Tops Q1 EPS by 9c; Raises FY11 Outlook
-
Merck (MRK) Settles with J&J (JNJ); to Make One-Time Payment of $500M; Affirms FY11 Outlook
-
Q1 Earnings Season to Begin April 11th as Alcoa (AA) Leads the Way
-
Johnson & Johnson (JNJ) Q4 Profit Drops 12% on Numerous Recalls
-
Johnson & Johnson (JNJ) Reports In-Line Q4 EPS of $1.03; Guides FY11 Below the Street
-
Q4 Preview: Johnson & Johnson (JNJ) Looks for Cure to the Recall Blues
-
Johnson & Johnson (JNJ) Q3 Earnings Beat; Raises FY10 Guidance
-
Johnson & Johnson (JNJ) Reports Q3 EPS of $1.23, Beats by 8c; Raises FY10 Outlook
-
Alcoa Kicks Off Q3 with Earnings on October 7, Big Names to Follow (AAPL, F, JNJ, GOOG, C, More...)
-
Johnson & Johnson (JNJ) Down After Flat Q2 Earnings and Lower Guidance
-
J&J (JNJ) Reports Inline Q2 Adj-EPS of $1.21; Cuts FY10 EPS Guidance
Back to JNJ Stock Lookup
